Microglia in Glioblastomas: Molecular Insight and Immunotherapeutic Potential.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or original clinical data.
PubMed 38893093 · doi:10.3390/cancers16111972
What was done
This narrative review synthesized literature on the molecular interplay between glioblastoma (GBM) cells and central nervous system resident microglia. The authors reviewed mechanisms of local and systemic immunosuppression, microglial phenotypic polarization (pro-inflammatory M1 versus anti-inflammatory M2), secreted cytokine/chemokine profiles, and potential immunotherapeutic strategies targeting these interactions based on published studies.
What was found
The abstract reports no quantitative metrics, effect sizes, or trial numbers. It notes that glioblastoma has a median post-diagnosis survival of 15 months despite maximal resection, radiotherapy, and chemotherapy. Pathologically, GBM fosters tumor-immune escape through microglial phenotypic modulation, where anti-inflammatory (M2) phenotypes secrete factors that facilitate tumor growth and immune evasion.
Why it matters
Understanding the molecular mechanisms driving microglial polarization in the glioblastoma microenvironment identifies specific immunoregulatory targets needed to overcome therapeutic resistance and tumor-mediated immunosuppression.
Limits
The abstract describes a non-systematic narrative review with no defined search criteria, meta-analytic data, or original clinical findings. The binary M1/M2 microglial classification is a mechanistic simplification of dynamic in vivo immune states, and translational clinical efficacy remains unmeasured.
Cited by
- supports Glioblastoma brain tumors are uniformly fatal.